Global Primary Sclerosing Cholangitis Market Size Study & Forecast, by Type (Classic PSC, Small-Duct PSC, PSC Associated with Autoimmune Hepatitis) by Treatment Type, Symptom Control, and End User, and Regional Forecasts 2025-2035

The Global Primary Sclerosing Cholangitis (PSC) Market is valued at approximately USD 0.33 billion in 2024 and is anticipated to grow at a CAGR of 7.70% over the forecast period 2025-2035. PSC is a rare, chronic liver disorder characterized by progressive inflammation and fibrosis of the bile ducts, eventually leading to liver cirrhosis and failure. Management of PSC involves a combination of therapeutic interventions, symptom control, and monitoring, with treatments targeting disease progression and associated complications. The market is driven by increasing awareness of rare liver diseases, advancements in pharmacological treatments such as ursodeoxycholic acid and obeticholic acid, and rising global healthcare expenditure. Moreover, the growing prevalence of autoimmune disorders and the expansion of specialized liver care centers contribute to market growth.

Rising prevalence of PSC globally, combined with an enhanced focus on early diagnosis and innovative treatment strategies, has significantly propelled the demand for effective therapies. According to recent epidemiological studies, the incidence of PSC varies between 0.5 to 1.3 per 100,000 person-years, with higher rates observed in North America and Europe. The surge in autoimmune hepatitis-associated PSC cases and the development of targeted therapeutics create lucrative avenues for pharmaceutical companies. However, challenges such as limited treatment options, high therapy costs, and the complexity of clinical management may restrain growth during the forecast period.

The detailed segments and sub-segments included in the report are:

By Type:
• Classic PSC
• Small-Duct PSC
• PSC Associated with Autoimmune Hepatitis

By Treatment Type:
• Ursodeoxycholic Acid
• Obeticholic Acid
• Methotrexate
• Corticosteroids
• Others

By Symptom Control:
• Antihistamines
• Cholestyramine
• Antibacterials
• Opioid Antagonists
• Colestipol
• Others

By End User:
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

By Region:

North America
• U.S.
• Canada

Europe
• UK
• Germany
• France
• Spain
• Italy
• ROE

Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• RoAPAC

Latin America
• Brazil
• Mexico

Middle East & Africa
• UAE
• Saudi Arabia
• South Africa
• Rest of Middle East & Africa

Classic PSC Segment Expected to Dominate the Market

Classic PSC represents the largest segment by type, owing to its higher prevalence and well-established clinical recognition among hepatologists. The segment’s dominance is driven by the substantial patient base requiring long-term management and monitoring, as well as the availability of clinical protocols for treatment. Increasing research focus on disease-modifying agents and rising awareness campaigns are further consolidating its leading position.

Ursodeoxycholic Acid Leads in Revenue Contribution

Currently, ursodeoxycholic acid-based therapies generate the largest revenue, attributed to their widespread clinical adoption as first-line treatment for slowing disease progression and improving liver function. These therapies benefit from well-documented efficacy, extensive clinical trials, and their ability to address both symptomatic relief and biochemical improvement, making them the primary revenue driver within the treatment type segment.

The Global Primary Sclerosing Cholangitis Market is regionally diverse, with North America leading in market share due to advanced healthcare infrastructure, high disease awareness, and concentrated research activities. Europe maintains a strong position supported by reimbursement policies and robust hepatology networks. Asia Pacific is expected to emerge as the fastest-growing region, driven by increasing diagnosis rates, rising healthcare expenditure, and growing access to specialty liver care facilities. Latin America and the Middle East & Africa are experiencing gradual uptake due to enhanced disease awareness and expanding pharmacy networks.

Major market players included in this report are:
• Gilead Sciences, Inc.
• Intercept Pharmaceuticals, Inc.
• AbbVie Inc.
• Bristol-Myers Squibb Company
• Novartis AG
• Pfizer Inc.
• Takeda Pharmaceutical Company Limited
• Roche Holding AG
• Sanofi S.A.
• Johnson & Johnson Services, Inc.
• Merck & Co., Inc.
• Amgen Inc.
• Ipsen Pharma
• Mitsubishi Tanabe Pharma Corporation
• AstraZeneca PLC

Global Primary Sclerosing Cholangitis Market Report Scope:
• Historical Data – 2023, 2024
• Base Year for Estimation – 2024
• Forecast period – 2025-2035
• Report Coverage – Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
• Regional Scope – North America; Europe; Asia Pacific; Latin America; Middle East & Africa

The objective of the study is to define market sizes of different segments and countries in recent years and to forecast the values for the coming years. The report incorporates both qualitative and quantitative aspects of the industry, offering comprehensive insights into growth drivers, challenges, and potential opportunities. Additionally, it presents a detailed competitive landscape, key strategies employed by market leaders, and emerging micro-market opportunities for investment.

Key Takeaways:
• Market Estimates & Forecast for 10 years from 2025 to 2035.
• Annualized revenues and regional-level analysis for each market segment.
• Detailed analysis of the geographical landscape with country-level insights.
• Competitive landscape with information on major players in the market.
• Analysis of key business strategies and recommendations on future market approach.
• Analysis of the competitive structure of the market.
• Demand side and supply side analysis of the market.

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions. Show more